Back to results
US 8,722,352 B2Granted
Test for non-septic hypovolemic shock
AssigneeAnazyme
InventorJohn Rodenrys
Life of this patent
Estimating the term…
Abstract
Methods and kits for diagnosis and staging of non-septic shock are presented in which one or more trypsin protease activities are measured from a biological sample to so identify and/or stage non-septic shock.
Claims4
A method of testing a mammal for presence, progression or stage of non-septic hypovolemic shock, comprising:
- obtaining a blood sample from the mammal and removing a cellular fraction from the blood to so obtain a serum or plasma fraction;
- adding a substrate for trypsin to the serum or plasma fraction, and measuring a product formed from the substrate to thereby measure activity of the trypsin to obtain a test result;
- and
- using the test result, upon diagnosis of the mammal as having a shock condition, to ascertain at least one of presence, progression, and stage of non-septic hypovolemic shock in the mammal;
- wherein the step of using the test result comprises a step of correlating the test result with a corresponding test result of a healthy mammal, wherein an increased activity of the trypsin as compared to the healthy mammal is indicative of the at least one of the presence, progression, and stage of non-septic hypovolemic shock.
2 more elements
A method of testing a mammal for presence, progression or stage of non-septic hypovolemic shock, comprising:
- obtaining a blood sample from the mammal and removing a cellular fraction from the blood to so obtain a serum or plasma fraction;
- measuring a degradation product from a trypsin protease reaction in the serum or plasma fraction to obtain a test result;
- using the test result, upon diagnosis of the mammal as having a shock condition, to ascertain at least one of presence, progression, and stage of non-septic hypovolemic shock in the mammal;
- wherein the step of using the test result comprises a step of correlation with a corresponding test result of a healthy mammal, wherein an increased presence of the degradation product as compared to the healthy mammal is indicative of the at least one of the presence, progression, and stage of non-septic hypovolemic shock.
1 more element
Dependencies are inferred from the claim text.